Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up

被引：2

作者：

Abreu, D. Rodriguez ^{[1
]}

Reck, M. ^{[2
]}

Sendur, N. ^{[3
,4
]}

Park, K. ^{[5
]}

Lee, D. H. ^{[6
]}

Cicin, I. ^{[7
]}

Yumuk, P. F. ^{[8
]}

Orlandi, F. J. ^{[9
]}

Leal, T. A. ^{[10
]}

Soparattanapaisarn, N. ^{[11
]}

Langleben, A. ^{[12
]}

Califano, R. ^{[13
,14
]}

Medgyasszay, B. ^{[15
]}

Hsia, T-C. ^{[16
,17
]}

Otterson, G. A. ^{[18
]}

Woods, T. ^{[19
]}

Jensen, E. ^{[19
]}

Samkari, A. ^{[19
]}

Boyer, M. ^{[20
]}

机构：

[1] Univ Las Palmas Gran Canaria, Complejo Hosp Univ Insular Maternoinfant Gran Can, Las Palmas Gran Canar, Spain

[2] German Ctr Lung Res, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany

[3] Ankara Yildirim Beyazit Univ, Fac Med, Ankara, Turkey

[4] Ankara Yildirim Beyazit Univ, Ankara City Hosp, Ankara, Turkey

[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[6] Asan Med Ctr, Seoul, South Korea

[7] Trakya Univ, Edirne, Turkey

[8] Marmara Univ, Sch Med, Istanbul, Turkey

[9] Orlandi Oncol, Providencia, Chile

[10] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[11] Mahidol Univ, Siriraj Hosp, Bangkok, Thailand

[12] McGill Univ, St Marys Hosp ODIM, Dept Oncol, Montreal, PQ, Canada

[13] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England

[14] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[15] Veszprem Cty Lung Hosp, Farkasgyepu, Hungary

[16] China Med Univ, Taichung, Taiwan

[17] China Med Univ Hosp, Taichung, Taiwan

[18] Ohio State Univ, James Comprehens Canc Ctr, Columbus, OH USA

[19] Merck & Co Inc, Kenilworth, NJ USA

[20] Chris OBrien Lifehouse, Camperdown, NSW, Australia

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.02.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6MO

引用

页码：S30 / S31

页数：2